Cytoplasmic free calcium ions (Ca2") play a central role in excitation-contraction coupling of cardiac muscle. Abnormal Ca2" handling has been implicated in systolic and diastolic dysfunction in patients with end-stage heart failure. The current study tests the hypothesis that expression of genes encoding proteins regulating myocardial Ca2" homeostasis is altered in human heart failure. We analyzed RNA isolated from the left ventricular (LV) myocardium of 30 cardiac transplant recipients with end-stage heart failure (HF) and five organ donors (normal control), using cDNA probes specific for the cardiac dihydropyridine (DHP) receptor (the a, subunit of the DHPsensitive Ca2" channel) and cardiac calsequestrin of sarcoplasmic reticulum (SR). In addition, abundance of DHP binding sites was assessed by ligand binding techniques (n = 6 each for the patients and normal controls). There was no difference in the level of cardiac calsequestrin mRNA between the HF patients and normal controls. In contrast, the level of mRNA encoding the DHP receptor was decreased by 47% (P < 0.001 ) in the LV myocardium from the patients with HF compared to the normal controls. The number of DHP binding sites was decreased by 3548%. As reported previously, expression of the SR Ca2+-ATPase mRNA was also diminished by 50% (P < 0.001 ) in the HF group. These data suggest that expression of the genes encoding the cardiac DHP receptor and SR Ca2+-ATPase is reduced in the LV myocardium from patients with HF. Altered expression of these genes may be related to abnormal Ca2" handling in the failing myocardium, contributing to LV systolic and diastolic dysfunction in patients with end-stage heart failure. (J. Clin. Invest. 1992. 90:927-935.) 
Introduction
Cytoplasmic free calcium ions (Ca2") play critical second messenger functions in the regulation of numerous fundamental physiologic processes. The central role of Ca2" in regulating muscle contraction is well established (1) . Upon depolarization of the sarcolemma, extracellular Ca2' enters the cells through voltage-gated calcium channels and triggers the release ofCa2+ from sarcoplasmic reticulum (SR).' The released Ca2+ binds to troponin C, which allows the myosin head to interact with actin to generate force. Reuptake ofCa2+ from the cytosol is mediated by the Ca2+-ATPase of the SR, in which Ca 2+ is bound by calsequestrin and stored until the next cycle of excitation. Ca2+ is extruded from myocytes by the Na+/Ca2' exchanger and the Ca2+-ATPase of the sarcolemma.
Abnormal Ca2' handling observed in the ventricular myocardium from patients with end-stage heart failure has been suggested to play an important role in systolic and diastolic dysfunction observed in these patients (2) . It has been reported that the SR Ca2+ uptake rate of myocardium obtained from patients with heart failure is diminished by 50% (3) . These human studies are compatible with numerous animal studies of cardiac hypertrophy and failure, in which Ca2+ uptake rates by myocardial SR have been reported to be decreased (4-9, and reviewed in reference 10). The diminished rates of the SR Ca2+ uptake seem to be due to reduced expression of the Ca2+-ATPase gene both in animals (11) (12) (13) and humans ( 14, 15 ) . In contrast, Movsesian et al. have reported that rates ofthe SR Ca2+ uptake as well as immunodetectable levels of the SR Ca2+-ATPase protein remained unchanged in the left ventricular (LV) myocardium from cardiac transplant recipients with idiopathic dilated cardiomyopathy as compared to normal controls ( 16-18).
There have been several reports about changes in expression of other SR protein genes. The level of mRNA encoding phospholamban, a regulatory protein of the SR Ca2+-ATPase, has been shown to be decreased in the hypertrophied right ventricles obtained from rabbits with pulmonary constriction ( 12) and in endomyocardial biopsies from patients with end-stage heart failure ( 19) . Furthermore, the decreased level of mRNA encoding Ca2+-release channel (ryanodine receptor) was recently observed in the LV myocardium from patients with ischemic cardiomyopathy, but not from those with idiopathic dilated cardiomyopathy (20) . On the other hand, the study conducted by Movsesian et al. ( 18) has demonstrated that immunodetectable levels of phospholamban, cardiac calse-tein), or Ca2"-release channel were not different between patients with idiopathic dilated cardiomyopathy and normal controls. These data suggest that there remain some controversies concerning the expression of these SR proteins in diseased myocardium.
Several studies have examined changes in the density ofthe Ca2+ antagonist receptor of the a, subunit of the dihydropyridine (DHP)-sensitive Ca2+ channel (Ca2+ channel) in the myocardium from cardiomyopathic hamsters (21) (22) (23) (24) , rats with pressure overload (25, 26) or infarction (27) and patients with idiopathic dilated cardiomyopathy (28, 29) and hypertrophic cardiomyopathy (30) . In these diverse animal models and human diseases there have been conflicting findings on the abundance of DHP binding sites (reviewed in reference 3 1 ) . It remains uncertain whether the LV expression of the cardiac DHP receptor (Ca2+ channel) is normal in human advanced heart failure.
There is a long-standing concern that the use of Ca2+ channel blockers contributes to the worsening of heart failure in patients with pre-existing left ventricular dysfunction ( 32, 33 ) . The results from a series of recent clinical trials strongly support this concern (34-39, and reviewed in reference 40). Because Ca2+ channel blockers are widely used to treat angina pectoris or hypertension in patients with underlying LV dysfunction, it is important to gain more understanding ofexpression of the gene encoding the Ca2+ channel in the failing myocardium.
In order to characterize alterations in expression of the genes related to Ca2+ handling in human heart failure, we examined the levels of mRNAs encoding the cardiac DHP receptor, cardiac calsequestrin, and SR Ca2+-ATPase in the LV myocardium from patients with end-stage heart failure. In addition, we quantitated the number of DHP binding sites by ligand binding assay.
Methods
Subjects. We analyzed LV RNA isolated from 30 patients (15) ( (43, 44) . (b) Cardiac calsequestrin: a 1.9-kb Eco RI fragment generated from a cDNA clone IC3A, containing the entire coding region and 3' untranslated region of the canine cardiac calsequestrin (46) . (c) SR Ca2+-ATPase: a 0.7-kb Pst I fragment corresponding to carboxyl terminal and 3' untranslated region of cDNA clone pCA, specific for the rabbit cardiac/slow twitch skeletal muscle SR Ca2+-ATPase (47) . (d) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH): a 1.3-kb Pst I fragment generated from cDNA clone pUC-GAPDH 13, containing the entire coding region and a part of the 3' untranslated region of the rat GAPDH (48) . The cDNA probes were labeled by random priming method with [32P]dCTP (3,000 Ci/ mmol, New England Nuclear, Boston) and the ANP oligonucleotide with T4 polynucleotide kinase and 32P-'yATP (3,000 Ci/ mmol, New England Nuclear).
Quantitation ofmRNA. The filters were exposed at -80°C on X-ray films (X-OMAT, AR, Eastman Kodak Co., Rochester, NY) with intensifying screens (DuPont Co., Wilmington, DE). Relative amounts of mRNA species were determined by laser densitometry. No partially degraded RNA samples were used for densitometric analysis. Several exposures of X-ray films were obtained to ascertain the densitometric analysis was performed in the linear response range of the X-ray films. In order to confirm the accuracy of the densitometric analysis, phosphoimager analysis (Molecular Dynamics, Inc., Sunnyvale, CA) was performed in five patients. The same blots were also hybridized with GAPDH probe and the relative levels ofGAPDH mRNA in each sample were determined by densitometry. Densitometric scores of specific mRNAs were normalized to that of mRNA encoding GAPDH as an internal control for RNA loading and transfer. We used GAPDH as an internal control because the levels of this mRNA species were not different between the patients and controls (patients: 1.00±0. 15 vs. controls: 1.00±0.15, NS). GAPDH is constitutively expressed in most tis- Abbreviations: CAD, coronary artery disease (ischemic cardiomyopathy); CHD, congenital heart disease; CI, cardiac index; DCM, idiopathic dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; HW, heart weight; LVEDP, left ventricular end-diastolic pressure; LVEF, left ventricular ejection fraction; NA, not applicable; PCWP, pulmonary capillary wedge pressure.
sues and is the most widely accepted internal control in molecular biology literatures. Mean value of the normalized mRNA scores from the organ donors (normal controls) was arbitrarily set as 1.0 for each mRNA species. DHP binding assay. In a separate series of experiments, sarcolemmal membranes were prepared as previously described (49) from the left ventricles of six organ donors, four patients with ischemic cardiomyopathy and two patients with idiopathic dilated cardiomyopathy. Specimens weighing 270-850 mg were thawed, minced and homogenized in 10 mM histidine, 10 mM NaHCO3. After solubilization of contractile proteins in KC1, sarcolemmal membranes were sedimented at 40,000 g and resuspended in assay buffer (NaCl 150 mM, Tris 10 mM, pH 7.5) by Dounce homogenizer. The entire preparation was at 4°C. DHP binding was characterized by 18-point 3H-(+)PN200-1 10 vs. unlabeled ( +)PN200-1 10 
Results
Characterization ofthe cardiac DHP receptor cDNA probe. Fig.  1 shows the partial nucleotide and amino acid sequences of the rat cardiac DHP receptor cDNA (pCDHP) used in the present study. Sequence comparison with the published rabbit cardiac DHP receptor cDNA has revealed that the pCDHP corresponds to the nucleotides 2411-3712, spanning from the domain II-S6 to the domain III-S6 regions of the cardiac DHP receptor (43) . There was 92% (nucleotide) and 99.4% (amino acid) sequence identity between the pCDHP and the rabbit Dihydropyridine Receptor and Calsequestrin in Heart Failure 929 495 118 DHP receptor cDNA in these regions (Fig. 1) . This indicates that the pCDHP is a specific probe for the cardiac DHP receptor.
Developmental changes in expression of the cardiac DHP receptor and calsequestrin genes. In order to examine whether expression ofthe cardiac DHP receptor and calsequestrin genes undergoes developmental regulation, we performed Northern blot analysis using RNA samples isolated from human fetal ventricles ( 17 and 19 wk ofgestation) and normal adult ventricles. The DHP receptor cDNA probe detected a single mRNA species of -8 kb in all the human ventricular samples (Fig. 2  A) . The level of expression of the cardiac DHP receptor mRNA was much lower in the fetuses compared to the normal adults. Similarly, expression of the cardiac calsequestrin mRNA (Fig. 2 B) and that of the SR Ca2+-ATPase ( 15) were much lower in the fetal ventricles. In contrast to the rat heart, in which expression of the SR Ca2+ -ATPase and cardiac calsequestrin was shown to be regulated under different mechanisms during the fetal stage (50), our data suggest that expression of these SR protein genes seems to be regulated in parallel in the fetal human ventricles as shown in fetal rabbit hearts ( 51 ) .
Verification of the densitometric analysis by phosphoimager. In order to verify whether the densitometric analysis we used to quantitate the levels of specific mRNA species in this 2441 2633 study is accurate in measuring the DHP receptor mRNA (a low abundance message), we directly compared the results ofdensitometry of a Northern blot to those obtained by phosphoimager analysis of the same blot. As shown in Fig. 3 (bottom) , there was an excellent agreement between the densitometric scores and the counts obtained by phosphoimager (r = 0.998, P < 0.001 ). We elected not to use dot blot analysis to quantitate the DHP receptor mRNA because this method would not differentiate specific hybridization signals of the DHP receptor mRNA from nonspecific hybridization signals to 28S ribosomal RNA (see Fig. 2 A) .
Expression ofthe Ca2" regulatory protein genes in thefailing human myocardium. To determine whether expression of the Ca2' regulatory protein genes is altered in the failing human myocardium, we performed RNA blot analysis using RNA isolated from the left ventricles of organ donors (Controls) and patients with end-stage heart failure (CHF). Fig. 3 shows the results ofrepresentative RNA blot analyses using the specific DNA probes. The cDNA probe corresponding to cardiac DHP receptor (the a, subunit of the DHP-sensitive Ca2+ channel) hybridized with a single mRNA species of -8 kb in all the cases studied. The LV level ofthe DHP receptor mRNA was decreased in the patients with end-stage heart failure, due to both idiopathic dilated cardiomyopathy (DCM) and coronary artery disease (CAD), as compared with the normal con- Fig. 4 shows the results of densitometric determination of the relative abundance ofeach mRNA species and Fig. 5 shows the data from each individual patient in different etiologic categories. The densitometric score for each mRNA was normalized by the relative abundance of GAPDH as an internal control for loading and transfer. The mean value ofthe normalized scores ofthe organ donors (normal controls) was arbitrarily set at 1.0. The mean LV level of mRNA encoding the DHP receptor decreased by 47% (P < 0.001 ) in the patients with end-stage heart failure as compared to that of the organ donors (Fig. 4,  left) . There was no significant difference in the level of the DHP receptor mRNA between the patients with dilated cardiomyopathy (0.48±0.12) and those with ischemic cardiomyopathy (0.53±0.1 1) (Fig. 5, left) . The level of the DHP receptor mRNA appears decreased in patients with end-stage hypertrophic cardiomyopathy (HCM: mean 0.73) and congenital heart disease (CHD: mean 0.53), although the small numbers of patients in these groups do not allow us to perform the subgroup analysis.
In contrast to that ofthe DHP receptor mRNA, expression ofthe cardiac calsequestrin mRNA remained unchanged in the end-stage heart failure patients (Fig. 4, right) , regardless of the etiology of heart failure (DCM: 1.02+0.21, CAD: 1.01+0.27, P = NS) (Fig. 5, right) . In consensus with the previous report (14) , the mean level of the SR Ca2+-ATPase mRNA was de- 
Control
Heart Failure Control Heart Failure sion of the gene encoding cardiac calsequestrin in the LV myocardium from the patients with end-stage heart failure and normal controls. The levels of the mRNA encoding this protein were also normalized by that of GAPDH mRNA. In contrast to the DHP receptor, the level of cardiac calsequestrin mRNA did not differ significantly between the diseased (n = 30) and normal LV myocardium (n = 5).
creased by 50% (P < 0.001 ) in the failing myocardium ofthese patients ( 15) .
We homogenized the whole LV wall to isolate total cellular RNA. The whole ventricular wall consists not only of myocytes, but also of nonmyocytes. Therefore, changes in the relative amounts of myocytes and nonmyocytes may alter the relative abundances of cardiac mRNAs even though expression of these mRNAs in myocytes remains unchanged. However, our data cannot be attributed solely to a decrease in the percentage of myocytes because the level ofthe DHP receptor mRNA was classified by the underlying etiologies of heart failure. Abbreviations: Ctrl, normal control (organ donor); CHF, congestive heart failure; DCM, idiopathic dilated cardiomyopathy; CAD, ischemic cardiomyopathy; CHD, congenital heart disease; HCM, hypertrophic cardiomyopathy.
significantly depressed even after corrected for the level of the calsequestrin mRNA (a myocyte-specific gene product) in each patient, also regardless of the etiology of heart failure (Control: 0.96±0.20; DCM: 0.49±0.13; CAD: 0.55±0.14, P <0.001).
To determine whether end-stage heart failure is associated with alterations in the number of DHP binding sites, ligand binding experiments were conducted in a separate series of normal and congestive heart failure ventricles. A representative PN200-1 10 binding curve is shown in Fig. 6 . Ligand binding parameters are summarized in Table II . The dissociation constant for (+ )-PN200-110 binding to normal tissue was 265±46 pM and was unchanged in heart failure tissue (233±32 pM). Bound/total ligand is plotted on the ordinate; total [PN200-lO0], expressed in picomolar, on the abscissa. Binding to membranes from control heart are shown in squares and from a heart with LV failure in circles. The decrease in the PN200-l00 binding sites is evident by the downward displacement of the curve for the failing LV myocardium. Equilibrium binding isotherms demonstrated that binding was > 90% specific at PN200-100 concentrations near the KD. To examine whether expression of the genes encoding the Ca2' regulatory proteins is regulated in a coordinated manner in the failing human myocardium, we analyzed correlative relationships among the levels ofexpression ofthese genes. There were no significant correlations among the levels of mRNAs encoding the DHP receptor, SR Ca2+-ATPase or cardiac calsequestrin in the LV myocardium from the patients (data not shown).
Discussion
The present study demonstrates that the level of mRNA encoding DHP receptor in the failing adult myocardium was significantly diminished compared with normal controls. As reported previously ( 15 ), the level of the SR Ca2+-ATPase mRNA was also reduced in these failing ventricles. This diminished expression of these genes in the failing myocardium is not due to a generalized depression of cardiac gene expression, because the level of cardiac calsequestrin mRNA was not altered and that of atrial natriuretic peptide mRNA was markedly augmented in these ventricles ( 15) .
The current data demonstrated that expression of the a, subunit gene for the slow Ca>2 channel was diminished in the LV myocardium from patients with end-stage heart failure. This is the subunit that forms the actual pore for Ca2 entry into the heart cell and is the target for clinically used Ca>2 channel blockers (52). There was no change in ligand binding affinity, suggesting that at least the binding domain of the gene product is unaltered. Regardless of the method of normalization, the number of DHP binding sites is significantly reduced.
The signal for decreased expression of the Ca>2 channel a, subunit gene is uncertain, but may possibly be related to the high plasma catecholamine concentrations found in patients with end-stage heart failure that has been demonstrated to down-regulate adrenergic receptors (53) . Marsh (54) has demonstrated in a myocyte culture system that 3-adrenergic stimulation can produce concomitant down-regulation off3-adrenergic receptors and DHP binding sites.
The observation that expression ofDHP receptor mRNA is decreased in end-stage heart failure should not be interpreted to be of pathogenic importance, because only the terminal stage of the disease was examined. However, the decrease in abundance of DHP receptors in this setting may have clinical implications regarding further depression of excitation-contraction coupling by the clinical use of Ca" channel blockers.
This may explain, at least in part, the deleterious effects ofCa" channel blockers in patients with congestive heart failure (32) (33) (34) (35) (36) (37) (38) (39) (40) .
In contrast to our present observations, Rasmussen et al. (29) reported that the number of DHP (30) . Thus, it is possible that in HCM the number of DHP binding sites may be increased early in the course of the disease and that the number diminished less in the end-stage of the disease than for heart failure ofother etiologies. It should be noted that we examined expression ofDHP receptor mRNA in LV myocardium, while Wagner et al. (30) examined DHP binding in atrial tissue. Therefore, the differences observed may also be due to those between the atrium and ventricle.
Decreased myocardial expression of the SR Ca 2+-ATPase mRNA was observed in human heart failure ( 14, 15) and animal models of cardiac hypertrophy (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . These data are compatible with the diminished SR Ca>2 uptake rates shown in both human heart failure (3) and animal models ofmyocardial hypertrophy and failure (4-10, 11, 13), although ( 14) and there is no evidence that the level of the myosin heavy chain mRNA is increased in the failing hearts ( 14, 19) . Second, in order to "dilute" a muscle specific transcript by 50%, a magnitude of decline that we observed here, the cellular mass (not the number) of nonmyocytes should occupy at least half of the myocardium in the failing hearts. This is not what we observed in these hearts. Lack ofsignificant correlations among the levels ofmRNAs encoding the DHP receptor, SR Ca2+-ATPase, and cardiac calsequestrin in individual patients suggest that expression of these genes is regulated independently in the failing LV myocardium. This contrasts with developmental regulation in which the fetal expression is low for all three genes. Recently, Lompre et al. (50) reported that in the fetal and aged rat, ventricular expression of SR Ca2+-ATPase was diminished but that of cardiac calsequestrin remained unchanged. In rabbit skeletal muscle, denervation has been observed to change the composition of the SR Ca2+-ATPase and calsequestrin in the same manner as we observed in the LV myocardium from patients with end-stage heart failure (55) . Further studies are needed to elucidate the mechanisms and functional significance of the alteration in the relative abundance of mRNAs encoding these two SR proteins.
Some limitations of the present study should be noted. First, we measured DHP binding sites in sarcolemmal membranes, not the DHP receptor protein itself. An antibody specific to the human cardiac DHP receptor protein (none available currently) will be necessary to make a direct measurement of the level of the aI subunit of the Ca2+ channel. Second, because the ligand binding assay and mRNA measurement were independently performed, only three patients had both measurements done simultaneously, a number too small to make a correlation between the two parameters in individual patients. Therefore, at present we are unable to conclude that expression of DHP receptor is regulated at pretranslational level in individual patients. Perhaps an animal study with a detailed kinetics at mRNA and protein levels (56) would be a more suitable system to answer such a question. Third, we used organ donor hearts as normal controls. They are not matched to heart failure patient groups with respect to age, sex or other clinical parameters. Although these hearts appeared grossly normal, they were exposed to endogenous, and in some cases, low dose exogenous catecholamines in the patient prior to harvest. Our control subjects did not have major cardiac abnormalities, or no significant ventricular expression of atrial natriuretic peptide was observed in any case ( 15) . Finally, it is not possible to determine from this study whether the alterations in the DHP receptor gene expression are pathogenic for LV dysfunction in patients with end-stage heart failure, or are secondary processes induced by heart failure. Although it is likely that the latter is true, the altered expression of the genes encoding the DHP receptor and other Ca2" regulatory proteins may lead to disturbances in Ca2" homeostasis in failing myocardium and contribute to impairment of systolic and diastolic function in these patients (57) .
